A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
Completed · Phase 2 · NCT02985957
Conditions: Prostate Cancer
At a glance
- Research payments reported, 2025
- $3,947
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 351
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Nivolumab (biological), Ipilimumab (biological), Cabazitaxel (drug), Prednisone (drug)
- Dates
- Started 2017-03-26; completion 2025-01-07
- Results posted
- Yes
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
From ClinicalTrials.gov, last updated 2025-12-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $3,947 in research payments for this study in 2025 (2 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Samith Thomas Kochuparambil, MD Hematology & Oncology · Minneapolis, MN
- Ian D. Schnadig, M.D. Hematology & Oncology · Tualatin, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Minnesota Hematology / Oncology, PA $3,012
- Northwest Cancer Specialists, PC $935
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.